Cargando…

Sustainability of Intraocular Pressure Reduction of Travoprost Ophthalmic Solution in Subjects with Normal Tension Glaucoma

INTRODUCTION: We examined the sustainability of the intraocular pressure (IOP)-lowering efficacy of travoprost (0.004%) ophthalmic solution in subjects with normal tension glaucoma (NTG). METHODS: Travoprost ophthalmic solution was given once daily at 9 PM to subjects with newly diagnosed NTG or wit...

Descripción completa

Detalles Bibliográficos
Autores principales:	Naito, Tomoko, Okuma, Shinichi, Nagayama, Mikio, Mizoue, Shiro, Ozaki, Mineo, Namiguchi, Koji, Miyamoto, Kazuhisa, Tanito, Masaki, Yoshikawa, Keiji
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2016
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4833797/ https://www.ncbi.nlm.nih.gov/pubmed/26861847 http://dx.doi.org/10.1007/s12325-016-0297-6

Ejemplares similares

Travoprost with sofZia® preservative system lowered intraocular pressure of Japanese normal tension glaucoma with minimal side effects
por: Mizoue, Shiro, et al.
Publicado: (2014)

Factors affecting eye drop instillation in glaucoma patients with visual field defect
por: Naito, Tomoko, et al.
Publicado: (2017)

Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue
por: Nakano, Tadashi, et al.
Publicado: (2016)

Effect of travoprost on 24-hour intraocular pressure in normal tension glaucoma
por: Nomura, Yuya, et al.
Publicado: (2010)

Fixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study
por: Nakano, Tadashi, et al.
Publicado: (2015)

Relationship between progression of visual field defect and intraocular pressure in primary open-angle glaucoma
por: Naito, Tomoko, et al.
Publicado: (2015)

A randomized crossover study comparing tafluprost 0.005% with travoprost 0.004% in patients with normal-tension glaucoma
por: Mizoguchi, Takanori, et al.
Publicado: (2012)

The diurnal and nocturnal effects of travoprost in normal-tension glaucoma
por: Seibold, Leonard K, et al.
Publicado: (2014)

Sustained intraocular pressure reduction throughout the day with travoprost ophthalmic solution 0.004%
por: Dubiner, Harvey B, et al.
Publicado: (2012)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events
por: Tsumura, Toyoaki, et al.
Publicado: (2012)

Effect of trabeculectomy on visual field progression in Japanese progressive normal-tension glaucoma with intraocular pressure < 15 mmHg
por: Naito, Tomoko, et al.
Publicado: (2017)

Effect on Intraocular Pressure of Switching from Latanoprost and Travoprost Monotherapy to Timolol Fixed Combinations in Patients with Normal-Tension Glaucoma
por: Igarashi, Ryoko, et al.
Publicado: (2014)

Effects of BAK-free travoprost treatment for 3 years in patients with normal tension glaucoma
por: Inoue, Kenji, et al.
Publicado: (2012)

Safety and efficacy of travoprost solution for the treatment of elevated intraocular pressure
por: Quaranta, Luciano, et al.
Publicado: (2015)

Comparison of success rates in eye drop instillation between sitting position and supine position
por: Naito, Tomoko, et al.
Publicado: (2018)

Relationship between visual field progression and baseline refraction in primary open-angle glaucoma
por: Naito, Tomoko, et al.
Publicado: (2016)

Efficacy of travoprost for the treatment of patients with glaucoma
por: Zhang, Xiu-Li, et al.
Publicado: (2019)

Visual field defects and changes in macular retinal ganglion cell complex thickness in eyes with intrachoroidal cavitation are similar to those in early glaucoma
por: Okuma, Shinichi, et al.
Publicado: (2016)

Relationship between consecutive deterioration of mean deviation value and progression of visual field defect in open-angle glaucoma
por: Naito, Tomoko, et al.
Publicado: (2015)

Additive intraocular pressure-lowering effect of dorzolamide 1%/timolol 0.5% fixed combination on prostaglandin monotherapy in patients with normal tension glaucoma
por: Mizoguchi, Takanori, et al.
Publicado: (2011)

Stratification-Based Investigation of Adjunctive Brimonidine or Timolol to a Prostaglandin Analogue in Japanese Patients with Normal-Tension Glaucoma
por: Yoshikawa, Keiji, et al.
Publicado: (2021)

Travoprost in the management of open-angle glaucoma and ocular hypertension
por: Denis, Philippe, et al.
Publicado: (2007)

Changes in Anterior Segment Morphology of Iris Bombe before and after Laser Peripheral Iridotomy in Patients with Uveitic Secondary Glaucoma
por: Ikegawa, Wakako, et al.
Publicado: (2016)

Efficacy, safety, and improved tolerability of travoprost BAK-free ophthalmic solution compared with prior prostaglandin therapy
por: Henry, J Charles, et al.
Publicado: (2008)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events. [Corrigendum]
Publicado: (2013)

Bimatoprost ophthalmic solution 0.03% lowered intraocular pressure of normal-tension glaucoma with minimal adverse events [Corrigendum]
Publicado: (2013)

Feasibility study of sustained-release travoprost punctum plug for intraocular pressure reduction in an Asian population
por: Perera, Shamira A, et al.
Publicado: (2016)

Effect of quantitative intraocular pressure reduction on visual field defect progression in normal tension glaucoma under medical therapy applying Markov model
por: Yoshikawa, Keiji, et al.
Publicado: (2018)

Ocular Surface Disease with BAK preserved Travoprost and Polyquaternium 1(Polyquad) preserved Travoprost
por: Kumar, Suresh, et al.
Publicado: (2019)

Travoprost Liquid Nanocrystals: An Innovative Armamentarium for Effective Glaucoma Therapy
por: El-Gendy, Mohamed A., et al.
Publicado: (2023)

Effect of benzalkonium chloride–free travoprost on intraocular pressure and ocular surface symptoms in patients with glaucoma previously on latanoprost: an open-label study
por: Lopes, Joao F., et al.
Publicado: (2015)

The effects of selective laser trabeculoplasty and travoprost on circadian intraocular pressure fluctuations: A randomized clinical trial
por: Kiddee, Weerawat, et al.
Publicado: (2017)

Frequent self-monitoring of intraocular pressure can determine effectiveness of medications in eyes with normal tension glaucoma: A case report
por: Mizohata, Hideki, et al.
Publicado: (2022)

Travoprost Induced Granulomatous Anterior Uveitis
por: Chiam, Patrick
Publicado: (2011)

Effectiveness of ophthalmic solution preservatives: a comparison of latanoprost with 0.02% benzalkonium chloride and travoprost with the sofZia preservative system
por: Ryan, Gerard, et al.
Publicado: (2011)

First experience with BAK-free travoprost 0.004% in topical glaucoma medication
por: Gado, Ahmed Salah, et al.
Publicado: (2012)

Long-Term Effectiveness and Safety of Tafluprost, Travoprost, and Latanoprost in Korean Patients with Primary Open-Angle Glaucoma or Normal-Tension Glaucoma: A Multicenter Retrospective Cohort Study (LOTUS Study)
por: Kim, Joon-Mo, et al.
Publicado: (2021)

Is intraocular pressure reduction the key treatment for normal-tension glaucoma?
por: Chen, Mei-Ju
Publicado: (2020)

Treatment persistence and cost-effectiveness of latanoprost/latanoprost–timolol, bimatoprost/bimatoprost–timolol, and travoprost/travoprost–timolol in glaucoma: an analysis based on the United Kingdom general practitioner research database
por: Lafuma, Antoine, et al.
Publicado: (2011)

Efficacy of the travoprost/timolol fixed combination versus the concomitant use of travoprost 0.004% and timolol 0.1% gel formulation
por: Kozobolis, Vassilios, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_1bimjqil1771r96cqae9quonsk